AI-generated summary
The authors report a randomised trial of home photobiomodulation therapy combined with exercise in people with Parkinson's disease. Stages 1 and 2 showed no significant difference between active and sham groups. In the extended stage, participants who continued active treatment showed significant improvement on the primary timed up-and-go measure compared with those who stopped, although the design was not placebo-controlled for that stage.
- Who or what was studied
- People with Parkinson's disease
- Limits stated in the abstract
- The extended stage compared self-selected continuers with non-continuers rather than using randomised or placebo-controlled allocation, and the abstract does not report a statistically significant primary result for the placebo-controlled stages.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Background/Objective
Few treatment options improve symptoms and the quality of life of Parkinson's disease (PD); more treatment choices are needed. This study examined the effectiveness of photobiomodulation therapy (PBMt) combined with exercise to improve PD symptoms and quality of life.
Methods
Participants were randomised into Active (n = 32) or Sham (n = 31) PBMt groups. Stage 1 was an 8-week double-blind, randomised, placebo-controlled trial using either active or sham PBMt to the head, back of the neck and abdomen three times weekly at home, followed by a 4-week washout. Stage 2 was 8 weeks of active PBMt for all participants. In Stage 3, participants chose to continue active PBMt treatment ('continuers') or receive no PBMt treatment ('non-continuers') for up to 48 weeks. Participants continued vigorous exercise throughout the study. Participants were assessed on enrolment and after each stage. The primary outcome measure was timed up-and-go, with a range of secondary motor and non-motor outcomes, including UPDRS.
Results
There was no significant difference between the Active and Sham Groups after Stages 1 or 2, apart from minimal increase in MoCA score/cognition (Sham Group) in Stage 1. After Stage 3, continuers showed a significant improvement in the primary outcome measure compared to non-continuers. Anxiety and the motor experiences of daily living (MDS-UPDRS Part II) were also significantly improved, while other outcomes approached significance, including MDS-UPDRS Total score (p = 0.062).
Conclusions
As the largest study to date, results add increasing weight to previous clinical trials and highlight potential for at-home, scalable treatment as adjunctive therapy alongside medication and exercise.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation therapy, Photobiomodulation, Sham, Primary outcome, Montreal Cognitive Assessment, Placebo-controlled, Anxiety. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.